Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

Moucari, Rami; Martinot–Peignoux, Michelle; Mackiewicz, Vincent; Boyer, Nathalie; Ripault, Marie–Pierre; Castelnau, Corinne; Leclere, Laurence; Dauvergne, Agnès; Valla, Dominique; Vidaud, Michel; Nicolas–Chanoine, Marie–Hélène; Marcellin, Patrick

doi:10.3851/imp1458

Cited by 71 publications

(54 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the paradigm shifts, genotype is becoming a standard blood test used to determine treatment type and timing of treatment initiation. No clear pediatric data are available, but the adult-focused data substantiate the notion that genotype predicts response to IFN-α, with genotype A demonstrating better treatment response in Caucasians [16,17] and genotype B better response than genotype C in Asians [18]. These findings are likely to be true for children because most subjects of the adult-focused papers acquired their disease in childhood.…”

Section: Interferonsupporting

confidence: 58%

Update on the Management of Pediatric Chronic Hepatitis B

Erlichman

Haber

2011

Curr Hepatitis Rep

View full text Add to dashboard Cite

A primary challenge in the management of pediatric chronic hepatitis B (CHB) is the lack of established child-specific guidelines. Treatment decisions for children with CHB are extrapolated from the robust adult-focused treatment and management guidelines. However, the rationale for treating children differs from adults, and appropriate patient selection for treatment is imperative to avoid mutant virus development and an indefinite treatment course. Few approved therapies exist for children less than 10 years of age, a group who may benefit greatly from novel and effective therapeutics. It is hoped this gap will be met in the near future, as the field of CHB is rapidly evolving and new therapeutics come to market. This review focuses on the currently available pediatric data regarding treatment for CHB, and draws comparisons with adult-focused data where applicable.

show abstract

Section: Interferonsupporting

confidence: 58%

Update on the Management of Pediatric Chronic Hepatitis B

Erlichman

Haber

2011

Curr Hepatitis Rep

View full text Add to dashboard Cite

show abstract

“…A mixture of Asian and Caucasian patients participated in the validation trials, hence all major HBV genotypes were included [16,17]. It has previously been demonstrated that baseline HBsAg levels and the degree of HBsAg decline during PEG-IFN therapy for HBeAg-negative CHB vary according to the infecting HBV genotype [12,21]. Data from the PEG-IFN alfa-2a phase III registration trial showed that HBeAg-negative patients infected with HBV genotype D had the highest HBsAg levels at baseline, but also experienced a lower degree of ontreatment HBsAg decline compared with genotypes A-C [12].…”

Section: Discussionmentioning

confidence: 99%

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Rijckborst

Hansen

Ferenci

et al. 2012

Journal of Hepatology

156

144

View full text Add to dashboard Cite

“…The HBsAg kinetics during PEG-IFN treatment also varied among different HBV genotypes. For example, at the end of treatment, the mean decrease of HBsAg level was highest with genotype A infection, intermediate in genotypes B and D, and lowest in genotypes C and E. During follow-up, serum HBsAg levels continued to decrease in genotypes A and D, whereas rebound was observed in genotypes B, C, and E (Moucari et al 2009). A recent study further revealed that high positive predictive values for long-term virological response at 5-yr post-PEG-IFN treatment could be obtained by applying end-of-treatment genotype-specific qHBsAg cutoff levels: 75%, 47%, 71%, and 75% for genotypes A (,400 IU/ml), B (,50 IU/ ml), C (,75 IU/ml), and D (,1000 IU/ml), respectively (Brunetto et al 2013).…”

Section: Interferon-based Therapymentioning

confidence: 94%

Hepatitis B Virus Genotypes and Variants

Lin

Kao

2015

Cold Spring Harbor Perspectives in Medicine

202

139

View full text Add to dashboard Cite

At least 10 hepatitis B virus (HBV) genotypes (A to J) with distinct geographic distributions and several HBV mutants, including precore/core promoter mutations and pre-S/S deletion mutations, have been recognized to be not only predictive of liver disease progression but also associated with response to antiviral therapy. HBV genotype -specific pathogenesis may contribute to heterogeneous clinical outcomes in chronic hepatitis B patients across the world. For example, patients with HBV genotypes C and D infection have a lower rate of spontaneous HBeAg seroconversion. In addition, HBV genotypes C and D have a higher frequency of core promoter and pre-S mutations than genotypes A and B. Genotypes C and D also carry a higher lifetime risk of cirrhosis and HCC development than genotypes A and B. Core promoter and pre-S mutations also correlate with an increased risk of hepatocellular carcinoma (HCC). Therapeutically, genotypes A and B patients have a better response to interferon-based therapy than genotypes C and D patients, but the response to nucleos(t)ide analogs is comparable across different HBV genotypes. In conclusion, HBV genotypes and variants may serve as viral genetic markers to predict disease progression as well as help practicing physicians optimize individualized antiviral therapy in clinical practice.

show abstract

Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

Abstract: HBV genotype has a strong influence on serum HBsAg kinetics during PEG-IFN-alpha2a therapy in HBeAg-negative patients.

Cited by 71 publications

References 12 publications

Update on the Management of Pediatric Chronic Hepatitis B

Update on the Management of Pediatric Chronic Hepatitis B

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Hepatitis B Virus Genotypes and Variants

Contact Info

Product

Resources

About